What we do Oxygenta Pharmaceutical Ltd manufactures various pharmaceutical drugs, specializing in anti-ulcerative and anti-bacterial medicines, operating a plant in Andhra Pradesh, India. |
Founded in 1,990 |
Market share Niche player in Indian pharmaceutical manufacturing, focusing on contract and own production of anti-ulcer and antibacterial drugs. |
Problem solved Provides essential pharmaceutical products addressing gastrointestinal and antibacterial health issues. |
Top clients or who we serve Serves pharmaceutical companies via contract manufacturing and offers products to healthcare providers and patients (B2B and B2C). |
Key management - |
Our journey and innovations Started as S S Organics in 1990, became Oxygenta Pharma in 2021-22; expanded contract manufacturing after resuming production post-2015 fire incident. |
Where we operate Primarily operates within India with limited export sales. |
Top products or what we offer Produces Ciprofloxacin HCL, Pantaprozole Sodium, Gabapentin, and other anti-ulcer, anti-inflammatory, and antibacterial drugs. |
Top brands - |
Raw materials needed Active pharmaceutical ingredients and organic fine chemicals for drug manufacturing. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue mainly from recurring contract manufacturing and own product sales. |
Our industry position Moderate player focused on contract manufacturing, with growth potential in select pharmaceutical segments. |
Financial highlights FY 2024-25 revenue INR 109.3 crore; net loss INR 9.68 crore, up from previous year’s loss. |
Geographical revenue split Domestic sales constitute nearly all revenue; exports are negligible. |
Order book - |
Whats driving growth Increased contract manufacturing volume and scaling of own pharmaceutical production. |
Our future plans Stabilizing manufacturing operations and expanding marketing post recovery from past operational disruptions. |
Our green promise - |
Our people and values Committed workforce focused on quality manufacturing and compliance; culture emphasizes ethical business practices. |
Key challenges ahead Overcoming financial losses while scaling production and market penetration. |
Interesting facts The company survived a major fire in 2015 and restarted commercial operations, strengthening contract manufacturing ties. |
Risks and strategy Financial losses and scaling challenges; strategy focuses on contract manufacturing growth and product portfolio expansion. |
